drug hub

With its business-friendly environment and Texas Medical Center’s biomanufacturing project, TMC BioPort, the state proved an attractive investment location for other companies in 2025, too. Novartis plans to build two new radioligand therapy manufacturing facilities in Florida and Texas, and in October, the U.K.’s AstraZeneca opened an expanded manufacturing facility in Coppell to double the production